Mila has formed a partnership with SEVO Bioscience, a start-up that develops biomolecules, vaccines and biological products using genetically engineered microalgae, Mila said on 12 January 2026.
SEVO Bioscience, which operates in Montreal, Quebec and Sydney, Nova Scotia, will draw on Mila's expertise in artificial intelligence, modelling and complex data processing, and gain access to its events and innovation hub.
Through the partnership, SEVO launched a research project called the Synthetic Trait Identifier and Assembler (SYNTIA). It is an AI-driven protein design platform that combines synthetic biology and machine learning to engineer proteins optimised beyond natural biological limits.
Mila said the work could have a significant impact on the production of high-value specialty products.
"This partnership opens an entirely new way of accessing biology," said Dilan B. Jaunky, chief executive of SEVO Bioscience.